<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?DTDIdentifier.IdentifierValue article.dtd?><?DTDIdentifier.IdentifierType system?><?SourceDTD.DTDName article.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName bmc2nlm.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Exp Clin Cancer Res</journal-id><journal-title>Journal of Experimental &#x00026; Clinical Cancer Research : CR</journal-title><issn pub-type="ppub">0392-9078</issn><issn pub-type="epub">1756-9966</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1756-9966-28-134</article-id><article-id pub-id-type="pmid">19811659</article-id><article-id pub-id-type="doi">10.1186/1756-9966-28-134</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Stec</surname><given-names>Rafa&#x00142;</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>drrafals@wp.pl</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Grala</surname><given-names>Bart&#x00142;omiej</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>gralab@wp.pl</email></contrib><contrib id="A3" contrib-type="author"><name><surname>M&#x00105;czewski</surname><given-names>Micha&#x00142;</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>maczmich@cmkp.edu.pl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Bodnar</surname><given-names>Lubomir</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lubo@esculap.pl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Szczylik</surname><given-names>Cezary</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>cszczylik@wp.pl</email></contrib></contrib-group><aff id="I1"><label>1</label>Department of Oncology, Military Institute of Health Services, Warsaw, Poland</aff><aff id="I2"><label>2</label>Department of Pathology, Military Institute of Health Services, Warsaw, Poland</aff><aff id="I3"><label>3</label>Department of Clinical Physiology, Medical Center of Postgraduate Education, Warsaw, Poland</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>10</month><year>2009</year></pub-date><volume>28</volume><issue>1</issue><fpage>134</fpage><lpage>134</lpage><ext-link ext-link-type="uri" xlink:href="http://www.jeccr.com/content/28/1/134"/><history><date date-type="received"><day>1</day><month>8</month><year>2009</year></date><date date-type="accepted"><day>7</day><month>10</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Stec et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Stec et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Stec Rafa&#x00142; drrafals@wp.pl </dc:author><dc:title> Chromophobe renal cell cancer - review of the literature and potential methods of treating metastatic disease </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>Journal of Experimental &#x00026; Clinical Cancer Research 28(1): 134-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1756-9966(2009)28:1&#x0003c;134&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1756-9966</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Chromophobe renal cell carcinoma (ChRCC) is a subtype of renal cell carcinoma (RCC). ChRCC is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman. Eighty six percent of ChRCCs cases are diagnosed in stage 1 or 2. Prognosis of ChRCC is better than in other types of RCC. Five- and 10-year disease free survival (DFS) for ChRCC was 83.9% and 77.9%, respectively. Expression of immunohistological markers: cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 could be potentially helpful in diagnosis of different subtypes of RCC. From all conventional RCC, CD 117 was detected (overexpression) in membrane of cells ChRCC.</p><p>Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. On the basis for formulating research hypotheses which should be verified by prospective studies.</p></abstract></article-meta></front><body><sec><title>Epidemiology</title><p>Renal cell carcinoma (RCC) is rather a rare neoplasm (in Poland about 3% of all tumors). According to the most recent National Cancer Register in Poland, 2150 men and 1501 women were diagnosed with renal cancer in 2004 [<xref ref-type="bibr" rid="B1">1</xref>].</p><p>Approximately 200,000 new cases of RCC are diagnosed annually worldwide, while the number of deaths caused by RCC approaches 100,000. Cure can be obtained in 70-90% of patients in the TNM stage I, in 55-70% of patients in stage II, in 20-30% of patients in stage III, and in less than 10% in stage IV [<xref ref-type="bibr" rid="B2">2</xref>].</p><p>The 2004 World Health Organization (WHO) classification of RCC recognized several subtypes of RCC. Most common subtypes are: clear cell RCC (70%), papillary RCC (10-15%), chromophobe RCC (4-6%), collecting duct carcinoma (about 1%) and unclassified RCC (4-5%) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Chromophobe RCC (ChRCC) is diagnosed mainly in 6th decade of life. An incidence of ChRCC is similar in both men and woman [<xref ref-type="bibr" rid="B5">5</xref>]. 86% of ChRCCs are diagnosed in stage 1 or 2 [<xref ref-type="bibr" rid="B3">3</xref>]. Renal vein invasion is seen in about 5% of cases [<xref ref-type="bibr" rid="B5">5</xref>].</p><p>Incidence of metastatic disease in chromophobe renal cell carcinoma is 6-7% [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In summary of 28 cases based on 7 reports, most common metastatic sites were liver (39%) and lung (36%) [<xref ref-type="bibr" rid="B6">6</xref>].</p></sec><sec><title>Pathology</title><p>Chromophobe RCC was first described in patients by Thoenes in 1985 [<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Macroscopically, ChRCC is a solitary, circumscribed, and not capsulated mass with a homogeneous light brown cut surface. The median tumor size of ChRCC is 6.0 cm, and it is larger than that of other subtypes [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>Microscopically, it contains of large, polygonal cells with prominent cell membrane [<xref ref-type="bibr" rid="B5">5</xref>]. Cytoplasm is pale and resistant to staining with hematoxylin and eosin. ChRCC cells have irregular nuclei with perinuclear clear halo. The tumor blood vessels have thick walls and are eccentrically hyalinized [<xref ref-type="bibr" rid="B3">3</xref>].</p><p>Chromophobe RCC is a heterogeneous group including classic type, eosinophilic type and mixed type. Eosinophilic variant (containing greater than 80% eosinophilic cells) has areas similar to renal oncocytomas (nested, alveolar or sheetlike architecture with eosinophilic granularity, perinuclear clearing, peripheral accentuation of cytoplasm) and it is often bilateral (11%) and multifocal (22%). Classic type of chromophobe RCC (containing greater than 80% pale cells) is associated with necrosis or sarcomatoid change. It has alveolar or sheetlike architecture and cytoplasm with flocculent "soap-bubble" appearance. Chromophobe RCCs with mixed histology have variable architecture (containing admixture of pale and eosinophilic cells) [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>Microscopic tumor necrosis and sarcomatoid change are known to be aggressive with a high potential for distant metastases [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>One of the diagnostic criteria of ChRCC is Hale colloidal iron [<xref ref-type="bibr" rid="B5">5</xref>], another are intracytoplasmatic microvesicles between 250-400 nm in diameter [<xref ref-type="bibr" rid="B9">9</xref>] (Figure 1- Chromophobe renal cell carcinoma, HE, 200&#x000d7;; Figure 2 - Positive reaction showing the presence of colloidal iron in cytoplasm of ChRCC, 400&#x000d7;).</p><fig position="float" id="F1"><label>Figure 1</label><caption><p>Chromophobe renal cell carcinoma, HE, 200&#x000d7;.</p></caption><graphic xlink:href="1756-9966-28-134-1"/></fig><fig position="float" id="F2"><label>Figure 2</label><caption><p>Positive reaction showing the presence of colloidal iron in cytoplasm of ChRCC, 400&#x000d7;.</p></caption><graphic xlink:href="1756-9966-28-134-2"/></fig><p>They can be demonstrated by electron microscopy, which is not used routinely in diagnosis of chromophobe RCC.</p><p>The main diagnostic criteria of chromophobe RCC is morphology coupled with characteristic immunophenotype (diffuse CK7, and KIT positivity).</p><p>Variable expression patterns of cytokeratins (CK), vimentin, epithelial membrane antigen (EMA), CD10 and parvalbumin can be potentially helpful in diagnosis of different subtypes of RCC. Vimentin was reported positive in 0-21% of ChRCC, CD10 in 0-33% of ChRCC, CK7 in 60-100% of ChRCC, CK8 in 50% of ChRCC, CK18 in 100% of ChRCC, CK19 in 33% of ChRCC, CK20 in 12.5% of ChRCC, EMA 75-100% of ChRCC and parvalbumin 100% of ChRCC. Sometimes ChRCC can be mistaken for renal oncocytoma [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] (Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Expression of immunohistological markers of ChRCC</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Immunohistological markers of ChRCC</bold></td><td align="center"><bold>CK</bold><break/><bold>7</bold></td><td align="center"><bold>CK</bold><break/><bold>8</bold></td><td align="center"><bold>CK</bold><break/><bold>18</bold></td><td align="center"><bold>CK</bold><break/><bold>19</bold></td><td align="center"><bold>CK</bold><break/><bold>20</bold></td><td align="center"><bold>Vimentin</bold></td><td align="center"><bold>EMA</bold></td><td align="center"><bold>CD10</bold></td><td align="center"><bold>Parvalbumin</bold></td></tr></thead><tbody><tr><td align="left"><bold>Positive reactivity (%)</bold></td><td align="center">60-100</td><td align="center">50</td><td align="center">100</td><td align="center">33</td><td align="center">12.5</td><td align="center">0-21</td><td align="center">75-100</td><td align="center">0-33</td><td align="center">100</td></tr></tbody></table></table-wrap></sec><sec><title>Clinical and Histomorphological Features</title><p>Prognosis in ChRCC is better than in other types of RCC. Five- and 10-year DFS for chromophobe RCC was 83.9% and 77.9%, respectively [<xref ref-type="bibr" rid="B12">12</xref>]. The median time from nephrectomy to metastasis detection, and from metastasis detection to death were twice as long for ChRCC than for other subtypes of RCC (papillary, clear cell RCC) [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>In univariate analysis: sarcomatoid change (<italic>p &#x0003c; 0.001</italic>), microscopic necrosis (<italic>p = 0.019</italic>), tumor size (<italic>p = 0.025</italic>), pT stage (3.4 vs. 1.2; <italic>p = &#x0003c; 0.001</italic>), broad alveolar growth (<italic>p = 0.012</italic>), vascular invasion (<italic>p = 0.020</italic>), and Fuhrman nuclear grade (grade 4 vs.3 vs 2; <italic>p &#x0003c; 0.001</italic>) were associated with aggressive ChRCC behavior. Independent predictors (Multivariable Cox Regression) of aggressive ChRCC included: pT stage (pT 3.4 vs. pT 1.2; <italic>p = 0.025</italic>, relative hazard 3.4), sarcomatoid change (<italic>p = 0.013</italic>, relative hazard 4.7) and microscopic necrosis (<italic>p = 0.020</italic>, relative hazard 3.5) [<xref ref-type="bibr" rid="B6">6</xref>]. Other factors like: age, sex, histologic subtyping by clear, eosinophilic or mixed cell types, tubulocystic pattern, degenerate or symplastic atypia were not predictors of chromophobe RCC behavior.</p><p>The patients with aggressive phenotype of chromophobe RCC may be candidates for adjuvant therapies as they become available [<xref ref-type="bibr" rid="B6">6</xref>].</p><p>ChRCCs are hyperechogenic in ultrasound examination, CT imaging or MRI demonstrate homogeneous enhancement. A spoke-wheel pattern of contrast enhancement is characteristic for ChRCC and for onkocytoma [<xref ref-type="bibr" rid="B13">13</xref>]. Most of ChRCCs are sporadic, but sometimes they are associated with BHD (Birt-Hogg-Dub&#x000e8;) syndrome [<xref ref-type="bibr" rid="B14">14</xref>].</p></sec><sec><title>Genetic Syndrome associated with chromophobe RCC</title><p>BHD syndrome is an autosomal dominant disorder that includes: benign skin tumor (skin tags, fibrofolliculomas), renal epithelial neoplasms (ChRCC, oncocytoma) and spontaneous pneumothorax. Renal tumors are often multifocal and bilateral. BHD gene encodes potential tumor suppressor protein - folliculin on 17p11 [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>ChRCCs is characterized by length polymorphism such as loss of chromosomal material involving chromosomes: 1, 2, 3p, 6, 10, 13, 17p, 17q and 21 [<xref ref-type="bibr" rid="B16">16</xref>,<xref ref-type="bibr" rid="B17">17</xref>]. It may be helpful in distinguishing between clear, papillary and chromophobe subtypes of RCC.</p></sec><sec><title>Expression of CD117 (KIT)</title><p>KIT (CD117) is a type III receptor tyrosine kinase that plays a role in intracellular signal transduction in several cell types. It regulates apoptosis, cell differentiation, proliferation, chemotaxis, and adhesion. Pathologic activation of KIT through gain-of-function mutations leads to neoplasia of KIT-dependent and KIT-positive cell types in different systems: Cajal cells - gastrointestinal stromal tumors (GISTs), myeloid cells - myeloid leukemia. In addition, many tumors have positive KIT immunoreactivity: small cells carcinomas, adenoid cystic carcinoma, chromophobe, thymic and sometimes ovarian and breast carcinomas [<xref ref-type="bibr" rid="B18">18</xref>].</p><p>In normal tissue of kidney KIT showed weak immunoreactivity only in the cytoplasm of distal tubules [<xref ref-type="bibr" rid="B19">19</xref>]. From all RCCs, <italic>KIT </italic>gene product was detected (overexpression) in membrane of cells ChRCC (88-100%) [<xref ref-type="bibr" rid="B19">19</xref>,<xref ref-type="bibr" rid="B20">20</xref>]. This is in agreement with histogenetic origin of chromophobe RCC from distal tubules.</p><p>KIT expression in classic variant is more often than eosinophilic variant (82% vs. 67%) [<xref ref-type="bibr" rid="B21">21</xref>].</p><p>Thus, immunohistochemical detection of KIT expression appears to be useful in diagnosis and treatment of ChRCC.</p><p>Yamazaki et al. reported upregulation of <italic>c-kit </italic>gene expression in ChRCCs. The mechanism for the overexpression of KIT in ChRCC is unknown. They suggested that the KIT signal pathway in ChRCCs could be activated in an autocrine way [<xref ref-type="bibr" rid="B19">19</xref>]. In summary 70 cases, based on 4 reports investigators were unable to detect activating mutations within exon 17 of the <italic>c-kit </italic>gene [<xref ref-type="bibr" rid="B19">19</xref>-<xref ref-type="bibr" rid="B22">22</xref>]. Absence of <italic>c-kit </italic>mutation could be argue for potential effectiveness of imatinib therapy in patients with metastatic ChRCCs.</p></sec><sec><title>Potential targeted therapy for advanced ChRCC</title><p>Now we have three potentially active and targeted agents against CD 117: imatinib, dasatinib and nilotinib.</p><sec><title>Imatinib</title><p>as KIT tyrosine kinase inhibitor (TKI) is an accepted treatment of chronic eosinophilic leukemia, hypereosinophilic syndrome, chronic myeloid leukemia, myelodysplastic/myeloproliferate syndrome, acute lymphoblastic leukemia, dermatofibrosarcoma protuberans, gastrointestinal stromal tumors [<xref ref-type="bibr" rid="B18">18</xref>]. The targets for imatinib include: BCR/ABL, CD 117, PDGFRA (platelet-derived growth factor receptor) [<xref ref-type="bibr" rid="B23">23</xref>] and also DDR1 (discoidin domain receptor 1), NQO2 (quinone reductase QR2) [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>].</p></sec><sec><title>Dasatinib</title><p>is a second-line multikinase (besides BCR/ABL kinase) inhibitor. Dasatinib is used in patients with chronic myeloid leukemia or acute lymphoblastic leukemia with resistance or intolerance of imatinib. <italic>In vitro</italic>, it has approximately 325-fold greater potency than imatinib in inhibition of BCR/ABL kinase [<xref ref-type="bibr" rid="B26">26</xref>]. In phase II trial, dasatinib increased response rates by &#x0003e; 2-fold versus high-dose of imatinib. The targets for dasatinib include: BCR/ABL, CD 117, PDGFRA, DDR1, DDR2, Src family kinases and ephrin receptor kinases [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B27">27</xref>].</p></sec><sec><title>Nilotinib</title><p>is the result of modifications to the imatinib molecule [<xref ref-type="bibr" rid="B28">28</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Nilotinib like imatinib, inhibits BCR/ABL, CD 117, PDGFRA, NQO2, DDR1 [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B29">29</xref>]. Nilotinib also inhibits CSF-1R (colony-stimulating factor-1 receptor) [<xref ref-type="bibr" rid="B30">30</xref>] and EphB4 (ephrin receptor) [<xref ref-type="bibr" rid="B31">31</xref>]. Nilotinib was 43-60 times more potent than imatinib in cell lines (KBM5, KBM7) [<xref ref-type="bibr" rid="B32">32</xref>].</p><p>A phase II clinical trial confirmed activity of nilotinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia [<xref ref-type="bibr" rid="B33">33</xref>] (Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Targets for Imatinib, Dasatinib and Nilotinib</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Target spectrum</bold></td><td align="center"><bold>Imatinib</bold></td><td align="center"><bold>Dasatinib</bold></td><td align="center"><bold>Nilotinib</bold></td></tr></thead><tbody><tr><td align="left">BCR-ABL</td><td align="center">+</td><td align="center">+</td><td align="center">+</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">PDGFR</td><td align="center">+</td><td align="center">+</td><td align="center">+</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">c-KIT</td><td align="center">+</td><td align="center">+</td><td align="center">+</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Src family kinases</td><td align="center">-</td><td align="center">+</td><td align="center">-</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">Ephrin receptor kinases</td><td align="center">-</td><td align="center">+</td><td align="center">only EphB4</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">NQO2</td><td align="center">+</td><td align="center">-</td><td align="center">+</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">DDR1</td><td align="center">+</td><td align="center">+</td><td align="center">+</td></tr><tr><td colspan="4"><hr></hr></td></tr><tr><td align="left">CSF-1R</td><td align="center">-</td><td align="center">-</td><td align="center">+</td></tr></tbody></table></table-wrap><p>We realize that this treatment hypothesis is controversial. Up to now, we have not found cases of successful treatment in the literature. But we think, that prospective trials with these agents in ChRCC should clarify their use in the future.</p><p>Other interesting therapies for advanced ChRCC may include therapies used in advanced clear cell renal carcinoma (CCRCC). Both, <bold>sorafenib </bold>and <bold>sunitinib </bold>showed clinical activity in randomized clinical trials in treatment metastatic CCRCC [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>]. These are tyrosine kinases inhibitors including vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR) [<xref ref-type="bibr" rid="B36">36</xref>,<xref ref-type="bibr" rid="B37">37</xref>].</p><p>VEGF and PDGF are markers of angiogenesis which plays an essential role in tumor growth and metastatization. Overexpression VEGF and PDGF in RCCs is associated with defective von Hippel-Lindau (VHL) protein. It can induce the expression of the genes involving in angiogenesis through the hypoxia-inducible factor 1&#x003b1; (HIF-1&#x003b1;) pathway. <italic>VHL </italic>is inactivated in up to 80% of sporadic cases of clear-cell carcinoma [<xref ref-type="bibr" rid="B38">38</xref>].</p><p>ChRCC can be associated with high serum levels of VEGF, making VEGF-targeted therapy an attractive therapeutic option [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>In biochemical and cellular tests both agents inhibit CD 117. They seem to be next potential targeted therapy for advanced ChRCC [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>Choueiri et al. confirmed, that sunitinib and sorafenib are active agents in metastatic ChRCC: 75% of patients had stable disease (SD) more than 3 months and 25% had partial response (PR) [<xref ref-type="bibr" rid="B37">37</xref>] Table <xref ref-type="table" rid="T3">3</xref>.</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Activity Sorafenib and Sunitynib in ChRCC</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Agent</bold></td><td align="center"><bold>No. of patients</bold></td><td align="center"><bold>Median PFS (months)</bold></td><td align="center"><bold>Partial Response</bold><break/><bold>No. of patients</bold></td><td align="center"><bold>Stable Disease</bold><break/><bold>No. of patients</bold></td></tr></thead><tbody><tr><td align="left">Sunitinib</td><td align="center">7</td><td align="center">8.9</td><td align="center">1</td><td align="center">6</td></tr><tr><td colspan="5"><hr></hr></td></tr><tr><td align="left">Sorafenib</td><td align="center">5</td><td align="center">27.5</td><td align="center">2</td><td align="center">3</td></tr></tbody></table></table-wrap></sec></sec><sec><title>Conclusion</title><p>Currently, we do not have any effective treatment for the metastatic disease apart from surgical procedures. Overexpression of CD117 on cellular membranes of ChRCC could be a potential target for kinase inhibitors like: imatinib, dasatinib, nilotinib. The potential targets for other kinase inhibitors (sunitinib and sorafenib) in ChRCC seem to be VEGFR and PDGFR. In conclusion, these observations are the basis for formulating research hypotheses which should be verified in prospective studies.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>RS, LB, MM participated in the sequence alignment and drafted the manuscript. BG was responsible for pathomorphology. RS, CS was responsible for coordination. All authors read and approved the final manuscript.</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>Special thanks for Professor W. Kozlowski, The Head of Department of Pathomorphology, Military Institute of Health Services in Warsaw.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Wojciechowska</surname><given-names>U</given-names></name><name><surname>Didkowska</surname><given-names>J</given-names></name><name><surname>Tarnowski</surname><given-names>W</given-names></name><name><surname>Zato&#x000f1;ski</surname><given-names>W</given-names></name></person-group><article-title>Nowotwory z&#x00142;o&#x0015b;liwe w Polsce w 2004 roku</article-title><source>Zachorowania na nowotwory z&#x00142;o&#x0015b;liwe (stan na 30 czerwca 2006 roku); Warszawa</source><year>2006</year><fpage>94</fpage><lpage>101</lpage></citation></ref><ref id="B2"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Pawlicki</surname><given-names>M</given-names></name><name><surname>Siedlecki</surname><given-names>P</given-names></name></person-group><article-title>Nowotwory uk&#x00142;adu moczowo-p&#x00142;ciowego</article-title><source>W: Onkologia Kliniczna Maciej Krakowski (red)</source><year>2006</year><publisher-name>Wydawnictwo Medyczne Borgis; Warszawa</publisher-name><fpage>922</fpage><lpage>925</lpage></citation></ref><ref id="B3"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Eble</surname><given-names>JN</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name><name><surname>Sesterhenn</surname><given-names>IA</given-names></name></person-group><source>Tumors of The system and male genital organs</source><year>2004</year><publisher-name>Lyon, France: IARC Press</publisher-name></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheville</surname><given-names>JC</given-names></name><name><surname>Lohse</surname><given-names>CM</given-names></name><name><surname>Zincke</surname><given-names>H</given-names></name><name><surname>Weaver</surname><given-names>H</given-names></name><name><surname>Blute</surname><given-names>AL</given-names></name><name><surname>Michael</surname><given-names>L</given-names></name></person-group><article-title>Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma</article-title><source>Am J Surg Pathol</source><year>2003</year><volume>27</volume><fpage>612</fpage><lpage>624</lpage><pub-id pub-id-type="pmid">12717246</pub-id><pub-id pub-id-type="doi">10.1097/00000478-200305000-00005</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>SR</given-names></name><name><surname>Humphrey</surname><given-names>PA</given-names></name><name><surname>Jay</surname><given-names>R</given-names></name><name><surname>Narra</surname><given-names/></name><name><surname>Srigley</surname><given-names>JR</given-names></name><name><surname>Cortez</surname><given-names>AD</given-names></name><name><surname>Dalrymple</surname><given-names>NC</given-names></name><name><surname>Chintapalli</surname><given-names>KN</given-names></name></person-group><article-title>Common and uncommon Histologic Subtype of Renal Cell Carcinoma: Imaging Spectrum with Pathologic Correlation</article-title><source>Radiographics</source><year>2006</year><volume>26</volume><fpage>1795</fpage><lpage>1810</lpage><pub-id pub-id-type="pmid">17102051</pub-id><pub-id pub-id-type="doi">10.1148/rg.266065010</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Amin</surname><given-names>MB</given-names></name><name><surname>Paner</surname><given-names>GP</given-names></name><name><surname>Alvarado-Cabrero</surname><given-names/></name><name><surname>Alvarado-Cabrero</surname><given-names>I</given-names></name><name><surname>Young</surname><given-names>AN</given-names></name><name><surname>Stricker</surname><given-names>HJ</given-names></name><name><surname>Lyles</surname><given-names>RH</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name></person-group><article-title>Chromophobe Renal Cell Carcinoma: Histomorphologic Characteristics and Evaluation of Conventional Pathologic prognostic Parameters in 145 Cases</article-title><source>Am J Surg Pathol</source><year>2008</year><volume>32</volume><fpage>1822</fpage><lpage>1834</lpage><pub-id pub-id-type="pmid">18813125</pub-id><pub-id pub-id-type="doi">10.1097/PAS.0b013e3181831e68</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>SDW</given-names></name><name><surname>Manish</surname><given-names>I</given-names></name><name><surname>Patel</surname><given-names>IM</given-names></name><name><surname>Snyder</surname><given-names>ME</given-names></name><name><surname>Kattan</surname><given-names>MW</given-names></name><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Reuter</surname><given-names>VE</given-names></name><name><surname>Russo</surname><given-names>P</given-names></name></person-group><article-title>Effect of Papillary and Chromophobe Cell Type on Disease-Free Survival After Nephrectomy for Renal Cell Carcinoma</article-title><source>Ann of Surg Oncol;</source><year>2004</year><volume>11</volume><issue>1</issue><fpage>71</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">14699037</pub-id><pub-id pub-id-type="doi">10.1007/BF02524349</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thoenes</surname><given-names>W</given-names></name><name><surname>Storkel</surname><given-names>S</given-names></name><name><surname>Rumpelt</surname><given-names>MJ</given-names></name></person-group><article-title>Human chromophobe cell renal carcinoma</article-title><source>Virchows Arch Cell Pathol</source><year>1985</year><volume>48</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/BF02890129</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>SL</given-names></name><name><surname>Fishman</surname><given-names>IJ</given-names></name><name><surname>Shanon</surname><given-names>RL</given-names></name></person-group><article-title>Chromophobe Renal Cell Carcinoma With Extensive Calcification and Ossification</article-title><source>Ann of Diag Pathol</source><year>2002</year><volume>6</volume><issue>4</issue><fpage>244</fpage><lpage>247</lpage><pub-id pub-id-type="doi">10.1053/adpa.2002.34731</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Skinnider</surname><given-names>BF</given-names></name><name><surname>Flope</surname><given-names>AL</given-names></name><name><surname>Hennigar</surname><given-names>RA</given-names></name><name><surname>Lim</surname><given-names>SD</given-names></name><name><surname>Cohen</surname><given-names>C</given-names></name><name><surname>Tomboli</surname><given-names>P</given-names></name></person-group><article-title>Distribution of cytokeratins and Vimentin in adult renal neoplasms and normal renal tissue</article-title><source>Am J Surg pathol</source><year>2005</year><volume>29</volume><fpage>747</fpage><lpage>754</lpage><pub-id pub-id-type="pmid">15897741</pub-id><pub-id pub-id-type="doi">10.1097/01.pas.0000163362.78475.63</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martignoni</surname><given-names>G</given-names></name><name><surname>Pea</surname><given-names>M</given-names></name><name><surname>Chilosi</surname><given-names>M</given-names></name><name><surname>Brunelli</surname><given-names>M</given-names></name><name><surname>Scarpa</surname><given-names>A</given-names></name><name><surname>Colato</surname><given-names>C</given-names></name><name><surname>Tardanico</surname><given-names>R</given-names></name><name><surname>Zamboni</surname><given-names>G</given-names></name><name><surname>Bonetti</surname><given-names>F</given-names></name></person-group><article-title>Parvalbumin is constantly expressed in Chromophobe Renal Carcinoma</article-title><source>Mod Pathol</source><year>2001</year><volume>14</volume><issue>8</issue><fpage>760</fpage><lpage>767</lpage><pub-id pub-id-type="pmid">11504835</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3880386</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Patard</surname><given-names>J-J</given-names></name><name><surname>Leray</surname><given-names>E</given-names></name><name><surname>Rioux-Leclercq</surname><given-names>N</given-names></name><name><surname>Cindolo</surname><given-names>L</given-names></name><name><surname>Ficarra</surname><given-names>V</given-names></name><name><surname>Zisman</surname><given-names>A</given-names></name><name><surname>De La Taille</surname><given-names>A</given-names></name><name><surname>Tostain</surname><given-names>J</given-names></name><name><surname>Artibani</surname><given-names>W</given-names></name><name><surname>Abbou</surname><given-names>CC</given-names></name><name><surname>Lobel</surname><given-names>B</given-names></name><name><surname>Guill&#x000e9;</surname><given-names>F</given-names></name><name><surname>Chopin</surname><given-names>DK</given-names></name><name><surname>Mulders</surname><given-names>PFA</given-names></name><name><surname>Wood</surname><given-names>CG</given-names></name><name><surname>Swanson</surname><given-names>DA</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name><name><surname>Belldegrun</surname><given-names>AS</given-names></name><name><surname>Pantuck</surname><given-names>AJ</given-names></name></person-group><article-title>Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>12</issue><fpage>2763</fpage><lpage>2771</lpage><pub-id pub-id-type="pmid">15837991</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2005.07.055</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kondo</surname><given-names>T</given-names></name><name><surname>Nakazawa</surname><given-names>H</given-names></name><name><surname>Sakai</surname><given-names>F</given-names></name><name><surname>Tomo</surname><given-names>K</given-names></name><name><surname>Shiro</surname><given-names>O</given-names></name><name><surname>Yasunobu</surname><given-names>H</given-names></name><name><surname>Hiroshi</surname><given-names>T</given-names></name></person-group><article-title>Spoke-wheel-like enhancement as an important imaging finding of chromophobe cell renal carcinoma: carcinoma retrospective analysis on computed tomography and magnetic resonance imaging studies</article-title><source>Int Urol</source><year>2004</year><volume>11</volume><fpage>817</fpage><lpage>824</lpage><pub-id pub-id-type="doi">10.1111/j.1442-2042.2004.00907.x</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>D</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name></person-group><article-title>Molecular genetics of familial renal cell carcinoma syndromes</article-title><source>Clin Lab Med</source><year>2005</year><volume>25</volume><fpage>259</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">15848736</pub-id><pub-id pub-id-type="doi">10.1016/j.cll.2005.01.003</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vira</surname><given-names>MA</given-names></name><name><surname>Novakovic</surname><given-names>KR</given-names></name><name><surname>Pinto</surname><given-names>PA</given-names></name><name><surname>Linehan</surname><given-names>WM</given-names></name></person-group><article-title>Genetic basis of kidney cancer: a model for developing molecular-targeted therapies</article-title><source>BJU Int</source><year>2007</year><volume>99</volume><fpage>1223</fpage><lpage>1229</lpage><pub-id pub-id-type="pmid">17441915</pub-id><pub-id pub-id-type="doi">10.1111/j.1464-410X.2007.06814.x</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>TD</given-names></name><name><surname>Eble</surname><given-names>JN</given-names></name><name><surname>Cheng</surname><given-names>L</given-names></name></person-group><article-title>Application of molecular diagnostic techniques to renal epithelial neoplasms</article-title><source>Clin Lab Med</source><year>2005</year><volume>25</volume><fpage>279</fpage><lpage>303</lpage><pub-id pub-id-type="pmid">15848737</pub-id><pub-id pub-id-type="doi">10.1016/j.cll.2005.01.011</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>A</given-names></name><name><surname>Storkel</surname><given-names>S</given-names></name><name><surname>Thoenes</surname><given-names>W</given-names></name><name><surname>Kovacs</surname><given-names>G</given-names></name></person-group><article-title>Mitochondrial and chromosomal DNA alterations in human chromophobe renal cell carcinoma</article-title><source>J Pathol</source><year>1992</year><volume>167</volume><fpage>273</fpage><lpage>277</lpage><pub-id pub-id-type="pmid">1381433</pub-id><pub-id pub-id-type="doi">10.1002/path.1711670303</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miettinen</surname><given-names>M</given-names></name><name><surname>Lasota</surname><given-names>J</given-names></name></person-group><article-title>KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation</article-title><source>Appl Immunohistochem Mol Morphol</source><year>2005</year><volume>13</volume><issue>3</issue><fpage>205</fpage><lpage>220</lpage><pub-id pub-id-type="pmid">16082245</pub-id><pub-id pub-id-type="doi">10.1097/01.pai.0000173054.83414.22</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Sakamoto</surname><given-names>M</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Kanai</surname><given-names>Y</given-names></name><name><surname>Ohki</surname><given-names>M</given-names></name><name><surname>Hirohashi</surname><given-names>S</given-names></name></person-group><article-title>Overexpression of KIT in chromophobe renal cell carcinoma</article-title><source>Oncogene</source><year>2003</year><volume>22</volume><fpage>847</fpage><lpage>852</lpage><pub-id pub-id-type="pmid">12584564</pub-id><pub-id pub-id-type="doi">10.1038/sj.onc.1206153</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhen-Hua</surname><given-names>L</given-names></name><name><surname>Eun Mee</surname><given-names>H</given-names></name><name><surname>Eung Seok</surname><given-names>L</given-names></name><name><surname>Kim Chul</surname><given-names>W</given-names></name><name><surname>Kim Han</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name><name><surname>Kim</surname><given-names>Y-S</given-names></name></person-group><article-title>A distinct expression pattern and point mutation of c-kit in papillary renal cell carcinomas</article-title><source>Modern Pathology</source><year>2004</year><volume>17</volume><fpage>611</fpage><lpage>616</lpage><pub-id pub-id-type="pmid">15073597</pub-id><pub-id pub-id-type="doi">10.1038/modpathol.3800108</pub-id></citation></ref><ref id="B21"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Kr&#x00171;ger</surname><given-names>S</given-names></name><name><surname>Sotlar</surname><given-names>K</given-names></name><name><surname>Kausch</surname><given-names>I</given-names></name><name><surname>Horny</surname><given-names>HP</given-names></name></person-group><article-title>Expression of KIT (CD 117) in renal cell carcinoma and renal oncocytoma</article-title><year>2005</year><volume>68</volume><fpage>269</fpage><lpage>275</lpage></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>CC</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Chiang</surname><given-names>H</given-names></name></person-group><article-title>Overexpression of KIT (CD 117) in chromophobe renal cell carcinoma and renal oncocytoma</article-title><source>Am J Clin Pathol</source><year>2004</year><volume>121</volume><fpage>878</fpage><lpage>883</lpage><pub-id pub-id-type="pmid">15198361</pub-id><pub-id pub-id-type="doi">10.1309/A7M2XTMJQK0KPQER</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Shoemaker</surname><given-names>JS</given-names></name><name><surname>Corless</surname><given-names>CL</given-names></name><name><surname>Hollis</surname><given-names>D</given-names></name><name><surname>Demetri</surname><given-names>GD</given-names></name><name><surname>Bertagnolli</surname><given-names>MM</given-names></name><name><surname>Fletcher</surname><given-names>JA</given-names></name></person-group><article-title>Correlation of target kinase genotype with clinical activity of imatinib mesylate in patients with metastatic GI stromal tumors (GISTs) expressing KIT (KIT+) [abstract]</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><issue>16S</issue><fpage>3s</fpage><comment>Abstract 7</comment></citation></ref><ref id="B24"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Rix</surname><given-names>U</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><source>Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib</source><year>2008</year><volume>49</volume><issue>4</issue><publisher-name>Leukemia &#x00026; Lymphoma</publisher-name><fpage>615</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">18398720</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rix</surname><given-names>U</given-names></name><name><surname>Hantschel</surname><given-names>O</given-names></name><name><surname>Durnberger</surname><given-names>G</given-names></name><name><surname>Remsing Rix</surname><given-names>LL</given-names></name><name><surname>Planyavsky</surname><given-names>M</given-names></name><name><surname>Fernbach</surname><given-names>NV</given-names></name><name><surname>Kaupe</surname><given-names>I</given-names></name><name><surname>Bennett</surname><given-names>KL</given-names></name><name><surname>Valent</surname><given-names>P</given-names></name><name><surname>Colinge</surname><given-names>J</given-names></name><name><surname>K&#x000f6;cher</surname><given-names>T</given-names></name><name><surname>Superti-Furga</surname><given-names>G</given-names></name></person-group><article-title>Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets</article-title><source>Blood</source><year>2007</year><volume>110</volume><fpage>5055</fpage><lpage>4063</lpage><pub-id pub-id-type="doi">10.1182/blood-2007-07-102061</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O'Hare</surname><given-names/></name><name><surname>Walters</surname><given-names>DK</given-names></name><name><surname>Stoffregen</surname><given-names>DP</given-names></name><name><surname>Sherbenou</surname><given-names>DW</given-names></name><name><surname>Heinrich</surname><given-names>MC</given-names></name><name><surname>Deininger</surname><given-names>MWN</given-names></name><name><surname>Druker</surname><given-names>BJ</given-names></name></person-group><article-title>Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>6987</fpage><lpage>6993</lpage><pub-id pub-id-type="pmid">16203792</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0622</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kantarijan</surname><given-names>H</given-names></name><name><surname>Pasquini</surname><given-names>R</given-names></name><name><surname>Hamerschlak</surname><given-names>N</given-names></name><name><surname>Rousselot</surname><given-names>P</given-names></name><name><surname>Holowiecki</surname><given-names>J</given-names></name><name><surname>Jootar</surname><given-names>S</given-names></name><name><surname>Robak</surname><given-names>T</given-names></name><name><surname>Khoroshko</surname><given-names>N</given-names></name><name><surname>Masszi</surname><given-names>T</given-names></name><name><surname>Skotnicki</surname><given-names>A</given-names></name><name><surname>Hellmann</surname><given-names>A</given-names></name><name><surname>Zaritsky</surname><given-names>A</given-names></name><name><surname>Golenkov</surname><given-names>A</given-names></name><name><surname>Radich</surname><given-names>J</given-names></name><name><surname>Hughes</surname><given-names>T</given-names></name><name><surname>Countouriotis</surname><given-names>A</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name></person-group><article-title>Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial</article-title><source>Blood</source><year>2007</year><volume>109</volume><fpage>5143</fpage><lpage>5150</lpage><pub-id pub-id-type="pmid">17317857</pub-id><pub-id pub-id-type="doi">10.1182/blood-2006-11-056028</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wiesberg</surname><given-names>E</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name><name><surname>Breitenstein</surname><given-names>W</given-names></name><name><surname>Br&#x000fc;ggen</surname><given-names>J</given-names></name><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Ray</surname><given-names>A</given-names></name><name><surname>Huntly</surname><given-names>B</given-names></name><name><surname>Fabbro</surname><given-names>D</given-names></name><name><surname>Fendrich</surname><given-names>G</given-names></name><name><surname>Hall-Meyers</surname><given-names>E</given-names></name><name><surname>Kung</surname><given-names>AL</given-names></name><name><surname>Mestan</surname><given-names>J</given-names></name><name><surname>Daley</surname><given-names>GQ</given-names></name><name><surname>Callahan</surname><given-names>L</given-names></name><name><surname>Catley</surname><given-names>L</given-names></name><name><surname>Cavazza</surname><given-names>C</given-names></name><name><surname>Mohammed</surname><given-names>A</given-names></name><name><surname>Neuberg</surname><given-names>D</given-names></name><name><surname>Wright</surname><given-names>RD</given-names></name><name><surname>Gilliland</surname><given-names>DG</given-names></name><name><surname>Griffin</surname><given-names>JD</given-names></name></person-group><article-title>Characterization of AMN107, a selective inhibitor of native and mutant BCR-ABL</article-title><source>Cancer Cell</source><year>2005</year><volume>7</volume><issue>2</issue><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">15710326</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2005.01.007</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deininger</surname><given-names>MW</given-names></name></person-group><article-title>Nilotinib</article-title><source>Clin Cancer Res</source><year>2008</year><volume>14</volume><issue>13</issue><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-07-5015</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brownlow</surname><given-names>N</given-names></name><name><surname>Russell</surname><given-names>AE</given-names></name><name><surname>Saravanapavan</surname><given-names>H</given-names></name><name><surname>Wiesmann</surname><given-names>M</given-names></name><name><surname>Murray</surname><given-names>JM</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name><name><surname>Dibb</surname><given-names>NJ</given-names></name></person-group><article-title>Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis</article-title><source>Leukemia</source><year>2008</year><volume>22</volume><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="pmid">17851554</pub-id><pub-id pub-id-type="doi">10.1038/sj.leu.2404944</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weisberg</surname><given-names>E</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name><name><surname>Cowan-Jacob</surname><given-names>SW</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>JD</given-names></name></person-group><article-title>Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia</article-title><source>Nature Reviews Cancer</source><year>2007</year><volume>7</volume><fpage>345</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">17457302</pub-id><pub-id pub-id-type="doi">10.1038/nrc2126</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Golemovic</surname><given-names>M</given-names></name><name><surname>Verstovsek</surname><given-names>S</given-names></name><name><surname>Giles</surname><given-names>F</given-names></name><name><surname>Cortes1</surname><given-names>J</given-names></name><name><surname>Manshouri1</surname><given-names>T</given-names></name><name><surname>Manley</surname><given-names>PW</given-names></name><name><surname>Mestan</surname><given-names>J</given-names></name><name><surname>Dugan</surname><given-names>M</given-names></name><name><surname>Alland</surname><given-names>L</given-names></name><name><surname>Griffin</surname><given-names>JD</given-names></name><name><surname>Arlinghaus</surname><given-names>RB</given-names></name><name><surname>Sun</surname><given-names>T</given-names></name><name><surname>Kantarjian</surname><given-names>H</given-names></name><name><surname>Beran</surname><given-names>M</given-names></name></person-group><article-title>AMN107, a Novel Aminopyrfimidine Inhibitor of Bcr-Abl, Has <italic>In vitro </italic>Activity against Imatinib-Resistant Chronic Myeloid Leukemia</article-title><source>Cancer Res</source><year>2005</year><volume>11</volume><issue>13</issue><fpage>4941</fpage><lpage>4947</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2601</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kantarjian</surname><given-names>HM</given-names></name><name><surname>Giles</surname><given-names>F</given-names></name><name><surname>Gattermann</surname><given-names>N</given-names></name><name><surname>Bhalla</surname><given-names>K</given-names></name><name><surname>Alimena</surname><given-names>G</given-names></name><name><surname>Palandri</surname><given-names>F</given-names></name><name><surname>Ossenkoppele</surname><given-names>GJ</given-names></name><name><surname>Nicolini</surname><given-names>F-E</given-names></name><name><surname>O'Brien</surname><given-names>SG</given-names></name><name><surname>Litzow</surname><given-names>M</given-names></name><name><surname>Bhatia</surname><given-names>R</given-names></name><name><surname>Cervantes</surname><given-names>F</given-names></name><name><surname>Haque</surname><given-names>A</given-names></name><name><surname>Shou</surname><given-names>Y</given-names></name><name><surname>Resta</surname><given-names>DJ</given-names></name><name><surname>Weitzman</surname><given-names>A</given-names></name><name><surname>Hochhaus</surname><given-names>A</given-names></name><name><surname>Philipp le</surname><given-names>Coutre</given-names></name></person-group><article-title>Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance</article-title><source>Blood</source><year>2007</year><volume>110</volume><issue>10</issue><fpage>3540</fpage><lpage>3546</lpage><pub-id pub-id-type="pmid">17715389</pub-id><pub-id pub-id-type="doi">10.1182/blood-2007-03-080689</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Hudson</surname><given-names>TE</given-names></name><name><surname>Tomczak</surname><given-names>P</given-names></name><name><surname>Michaelson</surname><given-names>D</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Rixe</surname><given-names>O</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>STBS</given-names></name><name><surname>Chen</surname><given-names>I</given-names></name><name><surname>Bycott</surname><given-names>PW</given-names></name><name><surname>Baum</surname><given-names>CM</given-names></name><name><surname>Figlin</surname><given-names>RA</given-names></name></person-group><article-title>Sunitynib versus interferon alfa in metastatic renal cell carcinoma</article-title><source>N Eng J Med</source><year>2007</year><volume>356</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa065044</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Escudier</surname><given-names>B</given-names></name><name><surname>Eisen</surname><given-names>T</given-names></name><name><surname>Stadler</surname><given-names>WM</given-names></name><name><surname>Szczylik</surname><given-names>C</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Siebels</surname><given-names>M</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Chevreau</surname><given-names>C</given-names></name><name><surname>Solska</surname><given-names>E</given-names></name><name><surname>Desai</surname><given-names>AA</given-names></name><name><surname>Rolland</surname><given-names>F</given-names></name><name><surname>Demkow</surname><given-names>T</given-names></name><name><surname>Hutson</surname><given-names>TEDO</given-names></name><name><surname>Gore</surname><given-names>M</given-names></name><name><surname>Freeman</surname><given-names>S</given-names></name><name><surname>Schwartz</surname><given-names>B</given-names></name><name><surname>Shan</surname><given-names>M</given-names></name><name><surname>Simantov</surname><given-names>R</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name></person-group><article-title>Sorafenib in advanced renal-cell carcinoma</article-title><source>N Eng J Med</source><year>2007</year><volume>356</volume><fpage>125</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa060655</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mendel</surname><given-names>DB</given-names></name><name><surname>Laird</surname><given-names>AD</given-names></name><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Louie</surname><given-names>SG</given-names></name><name><surname>Christensen</surname><given-names>JG</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Schreck</surname><given-names>RE</given-names></name><name><surname>Abrams</surname><given-names>TJ</given-names></name><name><surname>Ngai</surname><given-names>TJ</given-names></name><name><surname>Lee</surname><given-names>LB</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Carver</surname><given-names>J</given-names></name><name><surname>Chan</surname><given-names>E</given-names></name><name><surname>Moss</surname><given-names>KG</given-names></name><name><surname>Haznedar</surname><given-names>J&#x000d6;</given-names></name><name><surname>Sukbuntherng</surname><given-names>J</given-names></name><name><surname>Blake</surname><given-names>RA</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>T</given-names></name><name><surname>Shirazian</surname><given-names>S</given-names></name><name><surname>McMahon</surname><given-names>G</given-names></name><name><surname>Cherrington</surname><given-names>JM</given-names></name></person-group><article-title>In vivo antitumor activity of SU1 a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derive d growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship</article-title><source>Clin Cancer Res</source><year>1248</year><volume>9</volume><fpage>327</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">12538485</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choueiri</surname><given-names>TK</given-names></name><name><surname>Plantade</surname><given-names>A</given-names></name><name><surname>Elson</surname><given-names>P</given-names></name><name><surname>Negrier</surname><given-names>S</given-names></name><name><surname>Ravaud</surname><given-names>A</given-names></name><name><surname>Oudard</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Rini</surname><given-names>BI</given-names></name><name><surname>Bukowski</surname><given-names>RM</given-names></name><name><surname>Escudier</surname><given-names>B</given-names></name></person-group><article-title>Efficacy of Sunitynib and Sorafenib in Metastatic Papillary and Chromophobe Renal Cell Carcinoma</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><issue>1</issue><fpage>127</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">18165647</pub-id><pub-id pub-id-type="doi">10.1200/JCO.2007.13.3223</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Motzer</surname><given-names>RJ</given-names></name><name><surname>Bander</surname><given-names>NH</given-names></name><name><surname>Nanus</surname><given-names>DM</given-names></name></person-group><article-title>Renal-cell carcinoma</article-title><source>N Eng J Med</source><year>1996</year><volume>335</volume><fpage>865</fpage><lpage>875</lpage><pub-id pub-id-type="doi">10.1056/NEJM199609193351207</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schips</surname><given-names>L</given-names></name><name><surname>Dalpiaz</surname><given-names>O</given-names></name><name><surname>Lipsky</surname><given-names>K</given-names></name><name><surname>Langner</surname><given-names>C</given-names></name><name><surname>Rehak</surname><given-names>P</given-names></name><name><surname>Puerstner</surname><given-names>P</given-names></name><name><surname>Pummer</surname><given-names>K</given-names></name><name><surname>Zigeuner</surname><given-names>R</given-names></name></person-group><article-title>Serum levels of vascular endothelial growth factor VEGF) and endostatin in renal cell carcinoma patients compared to a control group</article-title><source>Eur Urol</source><year>2007</year><volume>51</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16844285</pub-id><pub-id pub-id-type="doi">10.1016/j.eururo.2006.06.026</pub-id></citation></ref></ref-list></back></article> 